BETHESDA, MdThe Adult AIDS Clinical Trials Group (AACTG) will
continue its research activities for another 5 years under a new
grant from the National Institute of Allergy and Infectious Diseases.
NIAID will provide the group $80 million in the first year of renewed funding.
Among the future priorities for the AACTG are defining the most
effective antiretroviral treatment strategies at each stage of HIV
infection, developing new ways to prevent or treat opportunistic
infections, and focusing on the growing problem of hepatitis C
co-infection with HIV disease, NIAID said in a news release
announcing the new funding.
Researchers also will study the interaction between various anti-HIV
drugs and seek to lessen metabolic abnormalities and other side
effects associated with combination therapy. Other problems that
AACTG scientists will address include the development of strategies
to eliminate lingering reservoirs of HIV within the body, finding new
ways to bolster the immune system in the presence of HIV, and the
pursuit of promising leads to restoring immune function.
AACTG, with 32 clinical trial units, has been a leader in defining
the standard of care for HIV-infected adults since its founding in
1987. Robert T. Schooley, MD, of the University of Colorado Health
Sciences Center, chairs the group.